Interim PET-guided ABVD or ABVD/escalated BEACOPP for newly diagnosed advanced-stage classic Hodgkin lymphoma (JCOG1305).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE
    • Publication Information:
      Publication: 2005- : Oxford : Wiley Publishing on behalf of the Japanese Cancer Association
      Original Publication: Tokyo : Japanese Cancer Association, c2003-
    • Subject Terms:
      Hodgkin Disease*/drug therapy ; Hodgkin Disease*/diagnostic imaging ; Hodgkin Disease*/pathology ; Antineoplastic Combined Chemotherapy Protocols*/therapeutic use ; Bleomycin*/administration & dosage ; Bleomycin*/therapeutic use ; Dacarbazine*/administration & dosage ; Dacarbazine*/therapeutic use ; Doxorubicin*/administration & dosage ; Doxorubicin*/therapeutic use ; Procarbazine*/administration & dosage ; Procarbazine*/therapeutic use ; Vincristine*/therapeutic use ; Vincristine*/administration & dosage ; Vinblastine*/administration & dosage ; Vinblastine*/therapeutic use ; Etoposide*/administration & dosage ; Etoposide*/therapeutic use ; Prednisone*/administration & dosage ; Prednisone*/therapeutic use ; Cyclophosphamide*/administration & dosage ; Cyclophosphamide*/therapeutic use ; Positron-Emission Tomography*/methods ; Neoplasm Staging*; Humans ; Adult ; Middle Aged ; Female ; Male ; Young Adult ; Adolescent ; Progression-Free Survival
    • Abstract:
      This single-arm confirmatory study (JCOG1305) aimed to evaluate the utility of interim positron emission tomography (iPET)-guided therapy for newly diagnosed advanced-stage classic Hodgkin lymphoma (cHL). Patients aged 16-60 years with cHL received two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and then underwent an iPET scan (PET2), which was centrally reviewed using a five-point Deauville scale. PET2-negative patients continued an additional four cycles of ABVD, whereas PET2-positive patients switched to six cycles of escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (eBEACOPP). The co-primary endpoints were 2-year progression-free survival (PFS) among all eligible and PET2-positive patients. Ninety-three patients were enrolled between January 2016 and December 2019. One patient was ineligible because of a diagnostic error. The median age of the 92 eligible patients was 35 (interquartile range, 28-48) years. Forty (43%) patients had stage III disease, and 43 (47%) had stage IV disease. The remaining nine (10%) patients had stage IIB disease with risk factors. Nineteen PET2-positive (21%) patients received eBEACOPP, 18 completed six cycles of eBEACOPP, 73 PET2-negative (79%) patients continued ABVD, and 70 completed an additional four cycles of ABVD. With a median follow-up period of 41.1 months, the 2-year PFS of 92 eligible patients and 19 PET2-positive patients were 84.8% (80% confidence interval [CI], 79.2-88.9) and 84.2% (80% CI, 69.7-92.1), respectively. Both primary endpoints were met at the prespecified threshold. This study demonstrates that iPET-guided therapy is a useful treatment option for younger patients with newly diagnosed advanced-stage cHL. Registration number: jRCTs031180218.
      (© 2024 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
    • References:
      J Clin Oncol. 2018 Feb 10;36(5):454-462. (PMID: 29360414)
      J Clin Oncol. 2007 Aug 20;25(24):3746-52. (PMID: 17646666)
      N Engl J Med. 1992 Nov 19;327(21):1478-84. (PMID: 1383821)
      J Clin Oncol. 2007 Feb 10;25(5):579-86. (PMID: 17242396)
      N Engl J Med. 2003 Jun 12;348(24):2386-95. (PMID: 12802024)
      N Engl J Med. 2016 Jun 23;374(25):2419-29. (PMID: 27332902)
      J Clin Oncol. 2016 Jun 10;34(17):2020-7. (PMID: 27069074)
      Br J Haematol. 2007 Jun;137(6):545-52. (PMID: 17459049)
      J Clin Oncol. 2013 Aug 1;31(22):2819-24. (PMID: 23796987)
      N Engl J Med. 2011 Jul 21;365(3):203-12. (PMID: 21774708)
      Int J Hematol. 2010 Dec;92(5):713-24. (PMID: 21076995)
      J Clin Oncol. 2024 Jan 1;42(1):13-18. (PMID: 37883739)
      Blood. 2019 Oct 10;134(15):1238-1246. (PMID: 31331918)
      Lancet Oncol. 2013 Sep;14(10):943-52. (PMID: 23948348)
      J Nucl Med. 2013 May;54(5):683-90. (PMID: 23516309)
      Eur J Nucl Med Mol Imaging. 2010 Oct;37(10):1824-33. (PMID: 20505930)
      J Clin Oncol. 2003 May 1;21(9):1734-9. (PMID: 12721249)
      Cancer. 1975 Jul;36(1):252-9. (PMID: 54209)
      Cancer Sci. 2024 Oct;115(10):3384-3393. (PMID: 39034771)
    • Grant Information:
      JP16ck0106220 Japan Agency for Medical Research and Development; 19ck0106509 Japan Agency for Medical Research and Development; 25-A-13 National Cancer Center Research and Development Funds; 26-A-4 National Cancer Center Research and Development Funds; 29-A-3 National Cancer Center Research and Development Funds; 2020-J-3 National Cancer Center Research and Development Funds; 2023-J-03 National Cancer Center Research and Development Funds
    • Contributed Indexing:
      Keywords: ABVD; advanced‐stage; cHL; escalated BEACOPP; interim PET‐guided
    • Accession Number:
      11056-06-7 (Bleomycin)
      7GR28W0FJI (Dacarbazine)
      80168379AG (Doxorubicin)
      35S93Y190K (Procarbazine)
      5J49Q6B70F (Vincristine)
      5V9KLZ54CY (Vinblastine)
      6PLQ3CP4P3 (Etoposide)
      VB0R961HZT (Prednisone)
      8N3DW7272P (Cyclophosphamide)
    • Subject Terms:
      ABVD protocol; BEACOPP protocol
    • Publication Date:
      Date Created: 20240722 Date Completed: 20241003 Latest Revision: 20241005
    • Publication Date:
      20241005
    • Accession Number:
      PMC11447878
    • Accession Number:
      10.1111/cas.16281
    • Accession Number:
      39034771